Cel AI PLC

Operating with its subsidiaries, Cel AI PLC produces and distributes consumer items infused with biosynthetic cannabinoids across the United Kingdom. Their product range includes cannabinoid-based solutions designed for both topical skincare and ingestible applications. These goods reach consumers through various channels: traditional retailers, direct online sales via the company's website, and other digital platforms. The organization, which began trading in 2018, was formerly named Cellular Goods PLC before officially adopting the Cel AI PLC moniker in February 2024. Its operational base is located in London, United Kingdom.

Cel AI PLC trades as CLAI.L on LSE. The company is classified in Consumer Defensive / Household & Personal Products and reports in GBP.

The current profile places the business in Household & Personal Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £17,942 of revenue and -£1.83M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Cel AI PLC can be compared against peers such as Agriterra Limited, Byotrol plc, East Imperial PLC, Ocean Harvest Technology Group plc, Real Good Food plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £815,126, beta of 0.36, and return on equity of -355.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CLAI.L currently shows total debt of £0 and beta of 0.36. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.getcel.ai

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.